Bristol-Myers Squibb
BMY
2,478 hedge funds and large institutions have $99.6B invested in Bristol-Myers Squibb in 2025 Q1 according to their latest regulatory filings, with 200 funds opening new positions, 953 increasing their positions, 987 reducing their positions, and 166 closing their positions.
20% more first-time investments, than exits
New positions opened: 200 | Existing positions closed: 166
8% more capital invested
Capital invested by funds: $91.9B → $99.6B (+$7.66B)
1.44% more ownership
Funds ownership: 78.86% → 80.3% (+1.4%)
2% more call options, than puts
Call options by funds: $1.73B | Put options by funds: $1.7B
0% less funds holding
Funds holding: 2,487 → 2,478 (-9)
3% less repeat investments, than reductions
Existing positions increased: 953 | Existing positions reduced: 987
10% less funds holding in top 10
Funds holding in top 10: 41 → 37 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$1.2B |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.03B |
| 3 |
JP Morgan Chase
New York
|
+$701M |
| 4 |
GQG Partners
Ft. Lauderdale,
Florida
|
+$698M |
| 5 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$268M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$553M |
| 2 |
Millennium Management
New York
|
-$462M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$339M |
| 4 |
Nordea Investment Management
Stockholm,
Sweden
|
-$284M |
| 5 |
VanEck Associates
New York
|
-$238M |
BMY Hedge Fund Activity: Q1 2025 in Review
2,478 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q1 2025, worth a combined $99.6B — up 8.3% from $91.9B a quarter earlier.
Buyers outnumbered sellers: 200 funds opened new BMY positions and 166 closed out — a net gain of 34 holders — while 953 added to existing stakes and 987 trimmed.
The largest buyer was Capital International Investors, adding an estimated $1.2B. The largest seller was Fidelity Investments, cutting an estimated $553M.
- 2,478 institutional investors held Bristol-Myers Squibb (BMY) as of Q1 2025, down from 2,487 in Q4 2024.
- Funds reported $99.6B of Bristol-Myers Squibb stock for Q1 2025, up 8.3% quarter-over-quarter.
- 200 funds opened new Bristol-Myers Squibb positions in Q1 2025 and 166 closed out, a net change of +34 holders.
- The largest Bristol-Myers Squibb buyer in Q1 2025 was Capital International Investors, an estimated $1.2B added.
- The largest Bristol-Myers Squibb seller in Q1 2025 was Fidelity Investments, an estimated $553M sold.
Based on aggregated 13F filings for Q1 2025.